Abstract:VPS35 deficiency or mutation can lead to dysfunction in autophagic–lysosomal pathways, abnormal protein accumulation, mitochondrial dysfunction, and impaired neuronal transmission, thereby promoting the onset of neurodegenerative diseases. Furthermore, VPS deficiency or mutation can result in defects in dendritic terminal differentiation, reduced neuronal proliferation, and increased inflammatory responses, inhibiting neurogenesis. The inhibition of neurogenesis exacerbates neurodegenerative diseases, which in turn suppress neurogenesis, creating a vicious cycle. A comprehensive understanding of the relationships between VPS35, neurogenesis, and neurodegenerative diseases is beneficial for elucidating the pathogenesis of neurodegenerative diseases. Targeting VPS35 in relation to neurogenesis holds promise for alleviating neurodegenerative diseases. Vacuolar protein sorting 35 (VPS35), a critical component of the retromer complex, plays a pivotal role in the pathogenesis of neurodegenerative diseases (NDs). It is involved in protein transmembrane sorting, facilitating the transport from endosomes to the trans‐Golgi network (TGN) and plasma membrane. Recent investigations have compellingly associated mutations in the VPS35 gene with neurodegenerative disorders such as Parkinson's and Alzheimer's disease. These genetic alterations are implicated in protein misfolding, disrupted autophagic processes, mitochondrial dysregulation, and synaptic impairment. Furthermore, VPS35 exerts a notable impact on neurogenesis by influencing neuronal functionality, protein conveyance, and synaptic performance. Dysregulation or mutation of VPS35 may escalate the progression of neurodegenerative conditions, underscoring its pivotal role in safeguarding neuronal integrity. This review comprehensively discusses the role of VPS35 and its functional impairments in NDs. Furthermore, we provide an overview of the impact of VPS35 on neurogenesis and further explore the intricate relationship between neurogenesis and NDs. These research advancements offer novel perspectives and valuable insights for identifying potential therapeutic targets in the treatment of NDs.

VPS35 Interacts with Dopamine Transportor and Disrupts Dopamine Transporter Recycling Pathway

Mutant VPS35-D620N Induces Motor Dysfunction and Impairs DAT-mediated Dopamine Recycling Pathway.

Mutant D620N and VPS35 induces motor dysfunction and impairs DAT-mediated dopamine recycling pathway

Vps35 Regulates Cell Surface Recycling and Signaling of Dopamine Receptor D1

Altered striatal dopamine levels in Parkinson’s disease VPS35 D620N mutant transgenic aged mice

VPS35 or retromer as a potential target for neurodegenerative disorders: barriers to progress

VPS35 and retromer dysfunction in Parkinson's disease

Mitochondrial and Clearance Impairment in p.D620N VPS35 Patient-Derived Neurons

VPS35 D620N Knockin Mice Recapitulate Cardinal Features of Parkinson’s Disease

VPS35-deficiency Results in an Impaired AMPA Receptor Trafficking and Decreased Dendritic Spine Maturation

Parkinson's disease–associated mutant VPS35 causes mitochondrial dysfunction by recycling DLP1 complexes

Parkinson's Disease-Associated Pathogenic VPS35 Mutation Causes Complex I Deficits.

Parkinson's Disease Causative Mutation in Vps35 Disturbs Tetherin Trafficking to Cell Surfaces and Facilitates Virus Spread

Parkinson’s Disease Causative Mutation in Vps35 Disturbs Tetherin Trafficking to Cell Surfaces and Facilitates Virus Spread

A Conserved Retromer Sorting Motif is Essential for Mitochondrial Dlp1 Recycling by Vps35 in Parkinson'S Disease Model

VPS35 Haploinsufficiency Increases Alzheimer’s Disease Neuropathology

Impaired neurogenesis in the hippocampus of an adult VPS35 mutant mouse model of Parkinson's disease through interaction with APP

Emergent glutamate & dopamine dysfunction in VPS35(D620N) knock-in mice and rapid reversal by LRRK2 inhibition

The impact of VPS35 D620N mutation on alternative autophagy and its reversal by estrogen in Parkinson's disease

Mechanistic study on the degradation of dopamine receptor D1 by VPS35

Exploring the triad: VPS35, neurogenesis, and neurodegenerative diseases